Following the recent FDA approval for vonoprazan (Voquenza) in the treatment of gastroesophageal reflux disease, Colin Howden, MD, professor of medicine at the University of Tennessee Health Science Center, joined for an interview to discuss the inner workings of the drug, patient monitoring, and potential future uses. Continue reading →

Enrollment is nearly complete in a clinical trial of the Sconeneuromodulation device in treating neurogenic, or overactive, bladder due to multiple sclerosis (MS), stroke, or spinal cord injury, SpineX, its developer, announced. Currently, 95 adult patients (more than 80% of planned total), ages 18 to 75, are taking part in the CONTINENCE study (NCT05301335) at sites in the U.S., Canada, and India Continue reading →

Higher blood levels of macrophage migration inhibitory factor (MIF), a molecule involved in inflammation, may predict a faster rate of brain shrinkage, or atrophy, in people with primary progressive multiple sclerosis (PPMS). Thats according to a new analysis of data from the SPRINT-MS Phase 2 trial (NCT01982942) that investigated ibudilast, an experimental oral MS therapy aiming to reduce inflammation in people with progressive forms of multiple sclerosis (MS). While previous trial data showed that ibudilast significantly slowed brain atrophy, the treatment had no effect on MIF levels over its two years. Continue reading →

Unveiling the Link Between Vitamin B and Multiple Sclerosis Recent scientific advancements have shed light on a potential molecular link between vitamin B and multiple sclerosis (MS), a neurodegenerative condition that affects millions worldwide. Continue reading →

LA JOLLA, Calif. Scientists have discovered a potential medical breakthrough in the treatment of multiple sclerosis. Researchers from Sanford Burnham Prebys unveiled a remarkable molecular connection between vitamin B12 and MS, occurring within astrocytes, non-neuronal glial cells in the brain Continue reading →